FDA Approves Krystal Gene Therapy For Rare Wound Disorder

The Food and Drug Administration on Friday approved the first topical gene therapy, clearing a treatment developed by Krystal Biotech for a rare genetic skin disease that causes severe skin blistering and has no cure.